EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis

Andrew A Girard, Brett W Sperry

Heart Failure Reviews · 01.10.2024 · 30 (1) · 69-73

DOI: 10.1007/s10741-024-10444-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Heart Failure Reviews, online erschienen am 01.10.2024. Verfasst von Andrew A Girard und 1 weiteren Autor:innen. Beteiligte Einrichtung: Saint Luke's Mid America Heart Institute, 4401 Wornall Road MO, Kansas City, 64111, USA. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This focused review will highlight the results of HELIOS-B, the first randomized outcomes trial evaluating a gene silencing treatment for transthyretin cardiac amyloidosis (ATTR-CM). In HELIOS-B, vutrisiran was tested against placebo and demonstrated a 28% reduction in the composite of all-cause mortality and recurrent cardiovascular events. Additionally, there were clinically significant benefits on the 6-min walk test, Kansas City Cardiomyopathy Questionnaire, and NYHA class. Discontinuation rates and adverse events were similar between treatment and control arms, suggesting that vutrisiran is well tolerated. In this review, these promising results are explored and compared with other treatment trials in ATTR-CM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesHumansRandomized Controlled Trials as TopicTreatment OutcomePrealbumin

Stichwörter der Autor:innen

CardiomyopathyTafamidisVutrisiran

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Saint Luke's Mid America Heart Institute, 4401 Wornall Road MO, Kansas City, 64111, USA.
  • University of Missouri-Kansas City, Kansas City, MO, USA.
  • Saint Luke's Mid America Heart Institute, 4401 Wornall Road MO, Kansas City, 64111, USA. bsperry@saint-lukes.org.
  • University of Missouri-Kansas City, Kansas City, MO, USA. bsperry@saint-lukes.org.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Girard, A. A., & Sperry, B. W. (2024). Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis. Heart Failure Reviews, 30(1), 69-73. https://doi.org/10.1007/s10741-024-10444-4

Vancouver

Girard AA, Sperry BW. Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis. Heart Failure Reviews. 2024;30(1):69-73. doi:10.1007/s10741-024-10444-4

BibTeX
@article{Girard2024,
  author = {Girard, Andrew A and Sperry, Brett W},
  title = {Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis},
  journal = {Heart Failure Reviews},
  year = {2024},
  volume = {30},
  number = {1},
  pages = {69--73},
  doi = {10.1007/s10741-024-10444-4}
}
Kostenlos starten →